Abu Dhabi and Sanofi partner to create new vaccine innovation center
阿布達比與賽諾菲攜手合作，建立全新疫苗創新中心
更新於: 2026年6月23日 上午07:30
Abu Dhabi is taking a giant leap forward in medical technology through a new strategic partnership with global biopharma leader, Sanofi.
阿布達比正藉由與全球生物製藥龍頭賽諾菲(Sanofi)公司展開全新策略合作，在醫療科技領域邁出巨大的一步。
Formalized at the 2026 BIO International Convention in San Diego, the two parties have signed a Memorandum of Understanding to explore the creation of a cutting-edge Vaccine Innovation Centre.
雙方於聖地牙哥舉行的2026年BIO國際生物技術大會上正式簽署諒解備忘錄，將共同探索創建一座尖端疫苗創新中心。
Located within Abu Dhabi’s HELM (Health, Endurance, Longevity, and Medicine) Cluster, the center aims to be a hub for scientific excellence.
該中心位於阿布達比的HELM（健康、耐力、長壽與醫學）聚落內，旨在成為科學卓越的樞紐。
The initiative focuses on high-tech solutions, including AI-driven vaccine discovery and advanced mRNA research.
此項倡議聚焦於高科技解決方案，包括以人工智慧驅動的疫苗研發，以及先進的mRNA研究。
By integrating research, academic expertise, and manufacturing infrastructure, the project creates an environment where innovators can move seamlessly from initial discovery to large-scale deployment.
透過整合研究、學術專業知識與製造基礎設施，該項目創造了一個讓創新者能夠順暢地從初始發現過渡到大規模部署的環境。
Beyond technical achievement, this partnership is a significant move toward global health security.
除了技術層面的成就，這次合作亦是邁向全球健康安全的重要舉措。
This collaboration is the latest in a series of efforts by Abu Dhabi to solidify its position as a global leader in life sciences, ensuring the region is better prepared for future public health challenges while pushing the boundaries of what is possible in modern medicine.
這次合作是阿布達比為鞏固其全球生命科學領導者地位而展開的系列努力之一，確保該地區能更好地應對未來公共衛生挑戰，同時突破現代醫學的極限。
